Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
NeoGenomics, Inc. - Common Stock
(NQ:
NEO
)
11.17
-0.28 (-2.45%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about NeoGenomics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
NEO INVESTOR ALERT: Gibbs Law Group Has Filed a Class Action Lawsuit on Behalf of NeoGenomics Investors
December 14, 2022
From
Gibbs Law Group
Via
Business Wire
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NeoGenomics, Inc. (NEO)
December 13, 2022
From
Glancy Prongay & Murray LLP
Via
Business Wire
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NeoGenomics, Inc. (NEO)
December 12, 2022
From
Law Offices of Howard G. Smith
Via
Business Wire
NeoGenomics Announces Chief Financial Officer Transition
December 05, 2022
Via
ACCESSWIRE
NeoGenomics Reports Third Quarter 2022 Results
November 08, 2022
Via
ACCESSWIRE
NeoGenomics and Liquid Biopsy Subsidiary Inivata and Collaborators to Present New Data at ESMO Congress 2022
September 07, 2022
Via
ACCESSWIRE
ROSEN, LEADING INVESTOR COUNSEL, Encourages NeoGenomics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NEO
December 11, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
Lawsuit
INVESTOR DEADLINE: NeoGenomics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – NEO
December 10, 2022
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
NEOGENOMICS INVESTOR ALERT: Gibbs Law Group Files Class Action Lawsuit on Behalf of NEO Investors
December 09, 2022
From
Gibbs Law Group
Via
Business Wire
NeoGenomics Reports Revenue of $125 Million in the Second Quarter
August 09, 2022
Via
ACCESSWIRE
NeoGenomics Announces Chief Executive Officer Appointment
July 21, 2022
Via
ACCESSWIRE
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of NeoGenomics, Inc. (NEO) Investors
December 09, 2022
From
Glancy Prongay & Murray LLP
Via
Business Wire
NEOGENOMICS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against NeoGenomics, Inc. - NEO
December 08, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of NeoGenomics, Inc. (NEO) Investors
December 08, 2022
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against NeoGenomics, Inc. (NEO)
December 07, 2022
From
Robbins LLP
Via
Business Wire
EQUITY ALERT: Rosen Law Firm Encourages NeoGenomics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – NEO
December 07, 2022
From
The Rosen Law Firm, P.A.
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of NeoGenomics, Inc. (NEO) Investors
December 07, 2022
From
Law Offices of Howard G. Smith
Via
Business Wire
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of NeoGenomics, Inc. (NEO) Investors
December 07, 2022
From
Kirby McInerney LLP
Via
Business Wire
INVESTOR ALERT: NeoGenomics, Inc. Investors with Substantial Losses Have Opportunity to Lead the NeoGenomics Class Action Lawsuit - NEO
December 07, 2022
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in NeoGenomics, Inc. with Losses of $100,000 to Contact the Firm
December 07, 2022
From
The Schall Law Firm
Via
Business Wire
CORRECTING and REPLACING NEOGENOMICS INVESTOR ALERT: Gibbs Law Group Files Class Action Lawsuit on Behalf of NEO Investors
December 06, 2022
From
Gibbs Law Group
Via
Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Files Class Action on Behalf of Investors in NeoGenomics, Inc. and Advises Shareholders with Losses of $100,000 to Contact the Firm
December 06, 2022
From
The Schall Law Firm
Via
Business Wire
NeoGenomics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 05, 2022
Via
ACCESSWIRE
Big Developments Set to be Unveiled at This Year’s San Antonio Breast Cancer Symposium (SABCS)
November 30, 2022
EQNX::TICKER_START (NASDAQ:ONCY),(NYSE:LLY),(NASDAQ:NEO),(NYSE:ZYME),(NASDAQ:GTHX) EQNX::TICKER_END
Via
FinancialNewsMedia
RaDaR(R) Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative Disease
November 21, 2022
Via
ACCESSWIRE
NeoGenomics and ImmunoGen Launch New Program Giving Ovarian Cancer Patients Access to Novel FR Biomarker Testing to Support the Launch of ELAHERE(TM)
November 18, 2022
Via
ACCESSWIRE
NeoGenomics Appoints David Perez, Industry Veteran and Former Terumo BCT CEO, to Its Board of Directors
November 07, 2022
Via
ACCESSWIRE
NeoGenomics Provides Update on MolDX Submission for CRC and RaDaR(TM) Commercial Launch
October 28, 2022
Via
ACCESSWIRE
NeoGenomics Schedules its Third Quarter 2022 Earnings Release for November 8, 2022
October 13, 2022
Via
ACCESSWIRE
NeoGenomics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 16, 2022
Via
ACCESSWIRE
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.